Assessing the role of drug interventions in the polycystic ovary syndrome model.

The research was devised to assess the prophylactic effects of agomelatine, a melatonin receptor antagonist, against letrozole-induced polycystic ovarian syndrome (PCOS) in 56 female rats divided randomly into seven groups of eight rats each. Group I served as the control and was exposed to behavioral tests such as the elevated plus maze (EPM) and Morri's water maze (MWM). Group II received 10 ml/kg of 1% carboxymethyl cellulose (CMC) orally for 28 days as a vehicle control. Groups III and IV were administered agomelatine orally at doses of 20 mg/kg and 40 mg/kg, respectively, for 28 days. To induce PCOS, Group V administered letrozole orally at a dose of 1 mg/kg for 21 days. On day 14 of the study, Groups VI and VII were also administered letrozole to induce PCOS, followed by agomelatine at 20 mg/kg and 40 mg/kg, respectively. Letrozole treatment brought about behavioral, biochemical, and histological abnormalities indicative of PCOS, including altered blood lipid and glucose levels, cognitive deficits, elevated oxidative stress, and impaired cholinergic function. Agomelatine significantly attenuated these adverse effects, demonstrating its potential as a therapeutic agent for PCOS. However, further research is necessary to elucidate its mechanisms of action and assess its clinical relevance in human PCOS treatment.